
                                SEQUENCE LISTING

<110> bluebird bio Inc.
      Down, Julian David
      Leboulch, Philippe Louis

<120> METHODS FOR ENHANCING THE DELIVERY OF
  GENE-TRANSDUCED CELLS

<130> BLBD-001/02WO

<140> PCT                  
<141> 2011-12-27 

<150> US 61/429,401
<151> 2011-01-03

<150> US 61/470,941
<151> 2011-04-01 

<160> 26

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 600
<212> DNA
<213> Artificial Sequence

<220> 
<223> Puromycin Resistance Gene

<400> 1
atgaccgagt acaagcccac ggtgcgcctc gccacccgcg acgacgtccc cagggccgta      60
cgcaccctcg ccgccgcgtt cgccgactac cccgccacgc gccacaccgt cgatccggac     120
cgccacatcg agcgggtcac cgagctgcaa gaactcttcc tcacgcgcgt cgggctcgac     180
atcggcaagg tgtgggtcgc ggacgacggc gccgccgtgg cggtctggac cacgccggag     240
agcgtcgaag cgggggcggt gttcgccgag atcggcccgc gcatggccga gttgagcggt     300
tcccggctgg ccgcgcagca acagatggaa ggcctcctgg cgccgcaccg gcccaaggag     360
cccgcgtggt tcctggccac cgtcggcgtc tcgcccgacc accagggcaa gggtctgggc     420
agcgccgtcg tgctccccgg agtggaggcg gccgagcgcg ccggggtgcc cgccttcctg     480
gagacctccg cgccccgcaa cctccccttc tacgagcggc tcggcttcac cgtcaccgcc     540
gacgtcgagg tgcccgaagg accgcgcacc tggtgcatga cccgcaagcc cggtgcctga     600

<210> 2
<211> 199
<212> PRT
<213> Artificial Sequence

<220> 
<223> Puromycin Resistance Protein

<400> 2
Met Thr Glu Tyr Lys Pro Thr Val Arg Leu Ala Thr Arg Asp Asp Val
 1               5                  10                  15
Pro Arg Ala Val Arg Thr Leu Ala Ala Ala Phe Ala Asp Tyr Pro Ala
            20                  25                  30
Thr Arg His Thr Val Asp Pro Asp Arg His Ile Glu Arg Val Thr Glu
        35                  40                  45
Leu Gln Glu Leu Phe Leu Thr Arg Val Gly Leu Asp Ile Gly Lys Val
    50                  55                  60
Trp Val Ala Asp Asp Gly Ala Ala Val Ala Val Trp Thr Thr Pro Glu
65                  70                  75                  80
Ser Val Glu Ala Gly Ala Val Phe Ala Glu Ile Gly Pro Arg Met Ala
                85                  90                  95
Glu Leu Ser Gly Ser Arg Leu Ala Ala Gln Gln Gln Met Glu Gly Leu
            100                 105                 110
Leu Ala Pro His Arg Pro Lys Glu Pro Ala Trp Phe Leu Ala Thr Val
        115                 120                 125
Gly Val Ser Pro Asp His Gln Gly Lys Gly Leu Gly Ser Ala Val Val
    130                 135                 140
Leu Pro Gly Val Glu Ala Ala Glu Arg Ala Gly Val Pro Ala Phe Leu
145                 150                 155                 160
Glu Thr Ser Ala Pro Arg Asn Leu Pro Phe Tyr Glu Arg Leu Gly Phe
                165                 170                 175
Thr Val Thr Ala Asp Val Glu Val Pro Glu Gly Pro Arg Thr Trp Cys
            180                 185                 190
Met Thr Arg Lys Pro Gly Ala
        195

<210> 3
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> Tobacco etch virus protease cleavage site

<220> 
<221> VARIANT        
<222> 2, 3, 5
<223> Xaa = Any amino acid

<220> 
<221> VARIANT        
<222> 7
<223> Xaa = Gly or Ser

<400> 3
Glu Xaa Xaa Tyr Xaa Gln Xaa
 1               5          


<210> 4
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> Tobacco etch virus protease cleavage site

<400> 4
Glu Asn Leu Tyr Phe Gln Gly
 1               5          


<210> 5
<211> 7
<212> PRT
<213> Artificial Sequence

<220> 
<223> Tobacco etch virus protease cleavage site

<400> 5
Glu Asn Leu Tyr Phe Gln Ser
 1               5          


<210> 6
<211> 19
<212> PRT
<213> Artificial Sequence

<220> 
<223> Exemplary self-cleaving polypeptide site
      comprising a 2A or 2A-like site.

<400> 6
Leu Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn
 1               5                  10                  15      
Pro Gly Pro
            


<210> 7
<211> 19
<212> PRT
<213> Artificial Sequence

<220> 
<223> Exemplary self-cleaving polypeptide site
      comprising a 2A or 2A-like site.

<400> 7
Thr Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn
 1               5                  10                  15      
Pro Gly Pro
            


<210> 8
<211> 14
<212> PRT
<213> Artificial Sequence

<220> 
<223> Exemplary self-cleaving polypeptide site
      comprising a 2A or 2A-like site.

<400> 8
Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro Gly Pro
 1               5                  10                  


<210> 9
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> Exemplary self-cleaving polypeptide site
      comprising a 2A or 2A-like site.

<400> 9
Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro Gly
 1               5                  10                  15      
Pro
    


<210> 10
<211> 20
<212> PRT
<213> Artificial Sequence

<220> 
<223> Exemplary self-cleaving polypeptide site
      comprising a 2A or 2A-like site.

<400> 10
Gln Leu Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser
 1               5                  10                  15      
Asn Pro Gly Pro
            20  


<210> 11
<211> 24
<212> PRT
<213> Artificial Sequence

<220> 
<223> Exemplary self-cleaving polypeptide site
      comprising a 2A or 2A-like site.

<400> 11
Ala Pro Val Lys Gln Thr Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly
 1               5                  10                  15      
Asp Val Glu Ser Asn Pro Gly Pro
            20                  


<210> 12
<211> 40
<212> PRT
<213> Artificial Sequence

<220> 
<223> Exemplary self-cleaving polypeptide site
      comprising a 2A or 2A-like site.

<400> 12
Val Thr Glu Leu Leu Tyr Arg Met Lys Arg Ala Glu Thr Tyr Cys Pro
 1               5                  10                  15      
Arg Pro Leu Leu Ala Ile His Pro Thr Glu Ala Arg His Lys Gln Lys
            20                  25                  30          
Ile Val Ala Pro Val Lys Gln Thr
        35                  40  


<210> 13
<211> 18
<212> PRT
<213> Artificial Sequence

<220> 
<223> Exemplary self-cleaving polypeptide site
      comprising a 2A or 2A-like site.

<400> 13
Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro
 1               5                  10                  15      
Gly Pro
        


<210> 14
<211> 40
<212> PRT
<213> Artificial Sequence

<220> 
<223> Exemplary self-cleaving polypeptide site
      comprising a 2A or 2A-like site.

<400> 14
Leu Leu Ala Ile His Pro Thr Glu Ala Arg His Lys Gln Lys Ile Val
 1               5                  10                  15      
Ala Pro Val Lys Gln Thr Leu Asn Phe Asp Leu Leu Lys Leu Ala Gly
            20                  25                  30          
Asp Val Glu Ser Asn Pro Gly Pro
        35                  40  


<210> 15
<211> 33
<212> PRT
<213> Artificial Sequence

<220> 
<223> Exemplary self-cleaving polypeptide site
      comprising a 2A or 2A-like site.

<400> 15
Glu Ala Arg His Lys Gln Lys Ile Val Ala Pro Val Lys Gln Thr Leu
 1               5                  10                  15      
Asn Phe Asp Leu Leu Lys Leu Ala Gly Asp Val Glu Ser Asn Pro Gly
            20                  25                  30          
Pro
    


<210> 16
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Polypeptide linker sequence

<400> 16
Asp Gly Gly Gly Ser
 1               5  


<210> 17
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Polypeptide linker sequence

<400> 17
Thr Gly Glu Lys Pro
 1               5  


<210> 18
<211> 4
<212> PRT
<213> Artificial Sequence

<220> 
<223> Polypeptide linker sequence

<400> 18
Gly Gly Arg Arg
 1              


<210> 19
<211> 5
<212> PRT
<213> Artificial Sequence

<220> 
<223> Polypeptide linker sequence

<400> 19
Gly Gly Gly Gly Ser
 1               5  


<210> 20
<211> 14
<212> PRT
<213> Artificial Sequence

<220> 
<223> Polypeptide linker sequence

<400> 20
Glu Gly Lys Ser Ser Gly Ser Gly Ser Glu Ser Lys Val Asp
 1               5                  10                  


<210> 21
<211> 18
<212> PRT
<213> Artificial Sequence

<220> 
<223> Polypeptide linker sequence

<400> 21
Lys Glu Ser Gly Ser Val Ser Ser Glu Gln Leu Ala Gln Phe Arg Ser
 1               5                  10                  15      
Leu Asp
        


<210> 22
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> Polypeptide linker sequence

<400> 22
Gly Gly Arg Arg Gly Gly Gly Ser
 1               5              


<210> 23
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> Polypeptide linker sequence

<400> 23
Leu Arg Gln Arg Asp Gly Glu Arg Pro
 1               5                  


<210> 24
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> Polypeptide linker sequence

<400> 24
Leu Arg Gln Lys Asp Gly Gly Gly Ser Glu Arg Pro
 1               5                  10          


<210> 25
<211> 16
<212> PRT
<213> Artificial Sequence

<220> 
<223> Polypeptide linker sequence

<400> 25
Leu Arg Gln Lys Asp Gly Gly Gly Ser Gly Gly Gly Ser Glu Arg Pro
 1               5                  10                  15      


<210> 26
<211> 10
<212> DNA
<213> Artificial Sequence

<220> 
<223> Consensus Kozak sequence

<400> 26
gccrccatgg                                                        10

